UniSuper Management Pty Ltd Boosts Holdings in Revvity, Inc. (NYSE:RVTY)

UniSuper Management Pty Ltd increased its stake in shares of Revvity, Inc. (NYSE:RVTY) by 24.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,399 shares of the company’s stock after purchasing an additional 3,671 shares during the period. UniSuper Management Pty Ltd’s holdings in Revvity were worth $2,054,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cerity Partners LLC raised its stake in Revvity by 7.4% in the 3rd quarter. Cerity Partners LLC now owns 17,130 shares of the company’s stock valued at $2,188,000 after purchasing an additional 1,174 shares during the last quarter. FMR LLC raised its position in shares of Revvity by 40.8% in the third quarter. FMR LLC now owns 155,556 shares of the company’s stock valued at $19,872,000 after buying an additional 45,040 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Revvity by 23.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,805 shares of the company’s stock worth $4,830,000 after buying an additional 7,237 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Revvity by 7.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 684,078 shares of the company’s stock worth $87,391,000 after acquiring an additional 48,700 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its stake in Revvity by 14.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 5,383 shares of the company’s stock valued at $688,000 after acquiring an additional 700 shares in the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Trading Down 1.6 %

Shares of NYSE RVTY opened at $105.65 on Monday. The stock has a fifty day simple moving average of $115.16 and a 200-day simple moving average of $117.14. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $12.69 billion, a PE ratio of 47.81, a PEG ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same quarter last year, the firm earned $1.25 EPS. On average, equities analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity’s dividend payout ratio is presently 12.67%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RVTY. KeyCorp boosted their target price on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Barclays boosted their price objective on Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and issued a $145.00 target price (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target on the stock in a research report on Friday, December 13th. Finally, Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.25.

Insiders Place Their Bets

In related news, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.68% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.